MA49903A - Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 - Google Patents

Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3

Info

Publication number
MA49903A
MA49903A MA049903A MA49903A MA49903A MA 49903 A MA49903 A MA 49903A MA 049903 A MA049903 A MA 049903A MA 49903 A MA49903 A MA 49903A MA 49903 A MA49903 A MA 49903A
Authority
MA
Morocco
Prior art keywords
sulphonylurides
sulphonylthiourides
nlrp3 inhibitors
nlrp3
inhibitors
Prior art date
Application number
MA049903A
Other languages
English (en)
Inventor
Thomas Alanine
Arregui Jokin Carrillo
Matthew Cooper
Angus Macleod
David Miller
Stuart Onions
Jonathan Shannon
Stephen St-Gallay
Ian Strutt
Stephen Thom
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713082.4A external-priority patent/GB201713082D0/en
Priority claimed from GBGB1718563.8A external-priority patent/GB201718563D0/en
Priority claimed from GBGB1721726.6A external-priority patent/GB201721726D0/en
Priority claimed from GBGB1721731.6A external-priority patent/GB201721731D0/en
Priority claimed from GBGB1810983.5A external-priority patent/GB201810983D0/en
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of MA49903A publication Critical patent/MA49903A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA049903A 2017-08-15 2018-08-15 Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 MA49903A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1713082.4A GB201713082D0 (en) 2017-08-15 2017-08-15 Novel compounds
GBGB1718563.8A GB201718563D0 (en) 2017-11-09 2017-11-09 Novel compounds
GBGB1721726.6A GB201721726D0 (en) 2017-12-22 2017-12-22 Novel compounds
GBGB1721731.6A GB201721731D0 (en) 2017-12-22 2017-12-22 Novel compounds
GBGB1810983.5A GB201810983D0 (en) 2018-07-04 2018-07-04 Novel compounds

Publications (1)

Publication Number Publication Date
MA49903A true MA49903A (fr) 2020-06-24

Family

ID=63364050

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049903A MA49903A (fr) 2017-08-15 2018-08-15 Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3

Country Status (18)

Country Link
US (2) US11613542B2 (fr)
EP (2) EP3668599A1 (fr)
JP (1) JP2020531453A (fr)
KR (1) KR20200041919A (fr)
CN (2) CN111093773A (fr)
AU (1) AU2018317798A1 (fr)
BR (1) BR112020003014A2 (fr)
CA (1) CA3071150A1 (fr)
CL (1) CL2020000367A1 (fr)
IL (1) IL272557A (fr)
MA (1) MA49903A (fr)
MX (1) MX2020001776A (fr)
PE (1) PE20200758A1 (fr)
RU (1) RU2020110219A (fr)
SG (1) SG11202001166RA (fr)
TW (1) TW201910316A (fr)
UY (1) UY37847A (fr)
WO (2) WO2019034690A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
HK1257569A1 (zh) 2016-02-16 2019-10-25 The University Of Queensland 磺醯脲和相关化合物及其用途
CA3047336A1 (fr) * 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Composes chimiques comme inhibiteurs de l'activite interleukine-1
JP7064097B2 (ja) 2017-03-17 2022-05-10 株式会社Mmag 植物病害防除剤
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3649112A1 (fr) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
US11773058B2 (en) 2017-08-15 2023-10-03 Inflazome Limited Sulfonamide carboxamide compounds
CN111032045B (zh) 2017-08-15 2023-08-15 安吉奥斯医药品有限公司 用于治疗血液病症的丙酮酸激酶激活剂
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
SG11202001164SA (en) * 2017-08-15 2020-03-30 Inflazome Ltd Novel sulfonamide carboxamide compounds
EP3668840A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
US20210122739A1 (en) * 2017-08-15 2021-04-29 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910316A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
EP3668843A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
EP3707137A1 (fr) * 2017-11-09 2020-09-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
WO2019166627A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
WO2019166619A1 (fr) * 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759073A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Dérivés de sulfonamide utilisés en tant qu'inhibiteurs de nlrp3
MA52489A (fr) 2018-05-04 2021-03-10 Inflazome Ltd Nouveaux composés
US20220267276A1 (en) 2018-07-03 2022-08-25 Novartis Ag Nlrp modulators
BR112021001044A2 (pt) 2018-07-20 2021-04-13 F. Hoffmann-La Roche Ag Compostos de sulfonimidamida como inibidores da atividade de interleucina-1
CA3104199A1 (fr) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Composes de sulfonyluree en tant qu'inhibiteurs de l'activite de l'interleukine 1
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
CN112672995A (zh) 2018-08-15 2021-04-16 英夫拉索姆有限公司 新型磺酰胺脲化合物
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
CN113056451A (zh) * 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
UY38687A (es) * 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
ES3056339T3 (en) 2019-06-12 2026-02-19 Nodthera Ltd Sulfonylurea derivatives and uses thereof
SI3983387T1 (sl) 2019-06-12 2024-09-30 NodThera Limited Derivati sulfoniluree in njihove uporabe
EP3986879B1 (fr) 2019-06-21 2024-10-02 AC Immune SA 1,2-thiazoles et 1,2-thiazines fusionnés qui agissent en tant que modulateurs de nlrp3
JP7723652B2 (ja) 2019-07-17 2025-08-14 ズーマゲン バイオサイエンシーズ エルティーディー 多発性硬化症（ＭＳ）の治療のためのＮＬＰＲ３モジュレーターとしてのＮ－（（１，２，３，５，６，７－ヘキサヒドロ－ｓ－インダセン－４－イル）カルバモイル）－４，５，６，７－テトラヒドロベンゾフラン－２－スルホンアミド誘導体および関連化合物
AU2020314186B2 (en) * 2019-07-17 2026-04-23 Zomagen Biosciences Ltd NLRP3 modulators
EP4013761A1 (fr) 2019-08-16 2022-06-22 Inflazome Limited Dérivés de sulfonylurée macrocycliques utiles en tant qu'inhibiteurs de nlrp3
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
CA3158123A1 (fr) 2019-11-12 2021-05-20 Yonggang Wei Derive d'amide et son procede de preparation et son application en medecine
JPWO2021132577A1 (fr) * 2019-12-27 2021-07-01
JP7843705B2 (ja) 2020-01-22 2026-04-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US20230121952A1 (en) 2020-02-18 2023-04-20 Inflazome Limited Compounds
US12599616B2 (en) * 2020-02-28 2026-04-14 Zydus Lifesciences Limited Subtituted sulfonylurea and sulfoximineurea derivatives
CN111217718B (zh) * 2020-03-11 2023-06-16 安徽东健化工科技有限公司 无硫2-溴-4-氟乙酰苯胺合成方法
EP4121059A4 (fr) 2020-03-16 2023-12-13 Zomagen Biosciences Ltd Modulateurs de nlrp3
CN111362835B (zh) * 2020-04-20 2022-08-30 苏州科晟通新材料科技有限公司 一种具有阻燃和抗水解功能的碳化二亚胺化合物及其制备方法
JP2023529867A (ja) 2020-06-05 2023-07-12 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤
CA3186041A1 (fr) * 2020-06-08 2021-12-16 Halia Therapeutics, Inc. Inhibiteurs de la kinase nek7
JP7504234B2 (ja) * 2020-06-11 2024-06-21 シーセン ファーマシューティカル カンパニー リミテッド ジメチルスルホキシミン誘導体
IL299084A (en) 2020-06-19 2023-02-01 Ac Immune Sa History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway
CN112022862B (zh) * 2020-08-21 2025-07-18 华东理工大学 磺酰脲类药物的抗衰老新用途
CN112137998A (zh) * 2020-10-10 2020-12-29 上海交通大学医学院附属新华医院 一种活性成分在制备防治坏死性小肠结肠炎药物中的应用
US20240391895A1 (en) * 2020-12-25 2024-11-28 Tuojie Biotech (Shanghai) Co., Ltd. Pyridazine-containing compound and medicinal use thereof
EP4293018A4 (fr) * 2021-02-10 2025-04-30 Hangzhou Innogate Pharma Co., Ltd. Composé servant d'inhibiteur de nlrp3
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
BR112023025318A2 (pt) 2021-06-04 2024-02-27 Hoffmann La Roche Derivados de triazina e seu uso no tratamento do câncer
AU2022356377A1 (en) * 2021-09-29 2024-04-11 Viva Star Biosciences (Suzhou) Co., Ltd. Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
TW202333678A (zh) * 2021-12-22 2023-09-01 大陸商瑞石生物醫藥有限公司 一種磺醯脲類化合物
US20250109126A1 (en) 2021-12-22 2025-04-03 Ac Immune Sa Dihydro-oxazol derivative compounds
EP4554945A1 (fr) 2022-07-14 2025-05-21 AC Immune SA Dérivés de pyrrolotriazine et d'imidazotriazine utilisés en tant que modulateurs de la voie de l'inflammasome nlrp3
CA3261365A1 (fr) 2022-07-28 2024-02-01 Ac Immune Sa Nouveaux composés
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
EP4719599A1 (fr) 2023-06-02 2026-04-08 Merck Sharp & Dohme LLC Hétérocyles bicycliques insaturés 5,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3
WO2025133307A1 (fr) 2023-12-22 2025-06-26 Ac Immune Sa Modulateurs hétérocycliques de la voie de l'inflammasome nlrp3
WO2025153532A1 (fr) 2024-01-16 2025-07-24 NodThera Limited Polythérapies faisant intervenir des inhibiteurs de nlrp3 et des agonistes de glp-1
WO2025153625A1 (fr) 2024-01-17 2025-07-24 Ac Immune Sa Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025153624A1 (fr) 2024-01-17 2025-07-24 Ac Immune Sa Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025163069A1 (fr) 2024-01-31 2025-08-07 Ac Immune Sa Nouveaux composés
WO2026057747A1 (fr) 2024-09-11 2026-03-19 Ac Immune Sa Utilisation thérapeutique de composés inhibiteurs de la voie de l'inflammasome nlrp3

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797474A (en) 1955-07-20 1958-07-02 Boehringer & Soehne Gmbh Sulphonylurea derivatives
NL129208C (fr) 1965-07-14
BE754588A (fr) 1969-08-07 1971-02-08 Hoechst Ag Thiophene-sulfonyl-urees et les medicaments qui contiennent cessubstances
AU571869B2 (en) 1983-05-09 1988-04-28 E.I. Du Pont De Nemours And Company Pyridyl- and pyrimidyl- sulphonamides
EP0126711B1 (fr) 1983-05-16 1989-08-02 Ciba-Geigy Ag Dérivés de pyrimidine actifs comme herbicides et régulateurs de croissance des plantes, leur préparation et leur usage
JPS6045573A (ja) 1983-08-22 1985-03-12 Nissan Chem Ind Ltd ピラゾ−ルスルホニルウレア誘導体，その製法および該誘導体を含有する選択性除草剤
US4723991A (en) 1984-03-23 1988-02-09 E. I. Du Pont De Nemours And Company Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity
US4659369A (en) 1984-08-27 1987-04-21 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
AU578307B2 (en) 1984-09-17 1988-10-20 E.I. Du Pont De Nemours And Company Herbicidal pyrazolesulfonamides
FI855180A7 (fi) 1985-01-18 1986-07-19 Nissan Chemical Ind Ltd Pyratsolisulfonamidijohdannainen, menetelmä sen valmistamiseksi ja sitä sisältävä rikkaruohomyrkky.
JPH0720958B2 (ja) * 1985-01-18 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホンアミド誘導体、製法および除草剤
CA1231336A (fr) 1985-05-30 1988-01-12 George Levitt Sulfonamides herbicides
JPH0720957B2 (ja) 1985-11-26 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホニルウレア誘導体、製法および除草剤
JP2570686B2 (ja) 1985-12-23 1997-01-08 日産化学工業株式会社 ピラゾ−ル誘導体
US4830660A (en) 1986-06-19 1989-05-16 Nissan Chemical Industries, Ltd. Imidazolesulfonamide derivatives and herbicides
ATE71096T1 (de) 1986-09-26 1992-01-15 Ciba Geigy Ag Aminopyrazinone und aminotriazinone.
US4802908A (en) * 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
US5356862A (en) * 1990-01-22 1994-10-18 E. I. Du Pont De Nemours And Company Herbicidal sulfonylureas
ZA915371B (en) 1990-07-17 1993-03-31 Lilly Co Eli Antitumor compositions and methods of treatment
EP0546082B1 (fr) 1990-08-29 1996-12-18 E.I. Du Pont De Nemours And Company Pyrrolesulfonylurees herbicides
DE4039733A1 (de) 1990-12-13 1992-06-17 Basf Ag Substituierte 5-aminopyrazole
JPH06510763A (ja) 1991-08-19 1994-12-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンジオテンシン２受容体遮断イミダゾリノン誘導体
JPH06510762A (ja) 1991-08-19 1994-12-01 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アンジオテンシン２受容体遮断イミダゾリノン誘導体
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH06199053A (ja) 1992-12-28 1994-07-19 Sankyo Kagaku Kk 感熱転写記録用色素
JPH06199054A (ja) 1992-12-28 1994-07-19 Dainippon Printing Co Ltd 熱転写シート
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
AU7007696A (en) 1995-09-22 1997-04-09 E.I. Du Pont De Nemours And Company Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines
WO1997011941A1 (fr) 1995-09-28 1997-04-03 Suntory Limited Derives de la quinazoline et leurs emplois
CA2247286A1 (fr) 1996-02-26 1997-08-28 Hirohiko Hasegawa Derives de sulfonylureidopyrazole
JP3573757B2 (ja) 1997-01-29 2004-10-06 ファイザー・インク スルホニルウレア誘導体、およびインターロイキン−１の活性を制御する上でのスルホニルウレア誘導体の使用
EP1270554A1 (fr) 1997-01-29 2003-01-02 Pfizer Inc. Dérivés de sulfonylurée et leur emploi dans le contrôle de l'activité de l'interleukine-1
US6022984A (en) 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
JP2000053649A (ja) 1998-08-11 2000-02-22 Sumitomo Pharmaceut Co Ltd スルホニルウレイドピラゾール誘導体
EP0987552A3 (fr) 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée
EA200100972A1 (ru) 1999-03-15 2002-02-28 Аксис Фармасьютикалз, Инк. Новые соединения и композиции как ингибиторы протеаз
EP1214087A1 (fr) * 1999-09-14 2002-06-19 Pfizer Products Inc. Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DE60114994T2 (de) 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco Blutplättchen-adp-rezeptor-inhibitoren
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2369967A1 (fr) 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methodes de traitement de maladies et de troubles relies au facteur nucleaire-kappa b
SK14102003A3 (sk) 2001-05-18 2004-08-03 Solvay Pharmaceuticals Gmbh Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv
FI110677B (fi) 2001-10-12 2003-03-14 Jujo Thermal Oy Lämpöherkkä tallennusmateriaali
SI1441734T1 (sl) 2001-10-26 2007-08-31 Angeletti P Ist Richerche Bio Dihidropirimidin karboksamidni inhibitorji HIV-integraze
BR0214810A (pt) 2001-11-30 2004-11-03 Pfizer Prod Inc Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação
RU2359967C2 (ru) 2002-05-28 2009-06-27 Джонсон энд Джонсон Фамэсьютикэл Рисеч энд Дивелопмент, эЛ.эЛ.Си Производные тиофена и фармацевтическая композиция (варианты)
US20040092529A1 (en) 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
JP4879745B2 (ja) 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド 置換イソキノリノン
WO2005032488A2 (fr) 2003-10-03 2005-04-14 Portola Pharmaceuticals, Inc. Sulfonylurees 2,4-dioxo-3-quinazolinylaryl
NZ554211A (en) 2004-09-29 2010-10-29 Portola Pharm Inc Substituted 2H-1,3-Benzoxazin-4(3H)-ones
WO2006085815A1 (fr) * 2005-02-11 2006-08-17 Astrazeneca Ab Derives de thiazole, leur processus de preparation et leur utilisation en therapie
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
WO2009065096A1 (fr) 2007-11-16 2009-05-22 University Of Medicine And Dentistry Of New Jersey Inhibiteurs de parasite à petites molécules fondés sur un mécanisme
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
ES2585287T3 (es) 2010-03-05 2016-10-04 Kyowa Hakko Kirin Co., Ltd. Derivado de pirazolopirimidina
EP2781216A4 (fr) * 2011-09-02 2015-05-27 Kyowa Hakko Kirin Co Ltd Régulateur d'activité de récepteur de chimiokine
PL221813B1 (pl) 2013-02-22 2016-05-31 Univ Medyczny W Lublinie Pochodne 1-arylo-6-benzenosulfonyloimidazo[1,2-a][1,3,5] triazyny oraz sposób ich otrzymywania
TW201501713A (zh) 2013-03-01 2015-01-16 Kyowa Hakko Kirin Co Ltd 眼炎症性疾病之預防及／或治療劑
SG11201603026PA (en) * 2013-11-05 2016-05-30 Novartis Ag Compositions and methods for modulating farnesoid x receptors
CN104513239B (zh) 2014-12-10 2017-08-22 沈阳药科大学 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
HUE055755T2 (hu) 2015-02-16 2021-12-28 Univ Queensland Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
US10688077B2 (en) 2015-02-26 2020-06-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
CA3008909C (fr) 2015-12-23 2023-10-03 The University Of British Columbia Promedicaments lies a des lipides
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
HK1257569A1 (zh) 2016-02-16 2019-10-25 The University Of Queensland 磺醯脲和相关化合物及其用途
WO2017184604A1 (fr) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Composés et compositions destinés au traitement d'états associés à une activité de nlrp
US11339136B2 (en) 2016-04-18 2022-05-24 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
WO2017189652A1 (fr) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs procédés d'utilisation
EP3272739A1 (fr) 2016-07-20 2018-01-24 NodThera Limited Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
CA3047336A1 (fr) * 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Composes chimiques comme inhibiteurs de l'activite interleukine-1
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
US11236045B2 (en) 2017-06-09 2022-02-01 Cadila Healthcare Limited Substituted sulfoximine compounds
KR102669722B1 (ko) 2017-07-07 2024-05-29 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
EP3649112A1 (fr) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
HUE066566T2 (hu) 2017-07-24 2024-08-28 Novartis Ag Vegyületek és készítmények NLRP aktivitással összefüggõ állapotok kezelésére
EP3658538B1 (fr) 2017-07-24 2023-04-19 Novartis AG Composés et compositions destinés au traitement d'états pathologiques associés à une activité nlrp
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
US11773058B2 (en) 2017-08-15 2023-10-03 Inflazome Limited Sulfonamide carboxamide compounds
EP3668840A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
EP3668843A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
TW201910316A (zh) * 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
SG11202001164SA (en) 2017-08-15 2020-03-30 Inflazome Ltd Novel sulfonamide carboxamide compounds
US20210122739A1 (en) 2017-08-15 2021-04-29 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019043610A1 (fr) 2017-08-31 2019-03-07 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
JP7157804B2 (ja) 2017-10-17 2022-10-20 ノバルティス アーゲー Ｎｌｒｐ活性に関連する病態を治療するためのスルホンアミド及びその組成物
PE20210050A1 (es) 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
WO2019092172A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
EP3707137A1 (fr) 2017-11-09 2020-09-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
CN110151749B (zh) 2018-02-13 2022-04-19 中国科学技术大学 冬凌草甲素在制备预防或治疗nlrp3炎症小体相关疾病的药物中的应用
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
EP3759089A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
WO2019166627A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
EP3759073A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Dérivés de sulfonamide utilisés en tant qu'inhibiteurs de nlrp3
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2019166619A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
MA52489A (fr) 2018-05-04 2021-03-10 Inflazome Ltd Nouveaux composés
US20220267276A1 (en) 2018-07-03 2022-08-25 Novartis Ag Nlrp modulators
CA3103664A1 (fr) 2018-07-03 2020-01-09 Novartis Ag Methodes de traitement ou de selection d'un traitement pour un sujet resistant a un inhibiteur de tnf a l'aide d'un antagoniste de nlrp3
CA3104199A1 (fr) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Composes de sulfonyluree en tant qu'inhibiteurs de l'activite de l'interleukine 1
CN112672995A (zh) 2018-08-15 2021-04-16 英夫拉索姆有限公司 新型磺酰胺脲化合物
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
PL3880660T3 (pl) 2018-11-13 2025-11-12 Novartis Ag Związki i kompozycje do leczenia stanów związanych z aktywnością nlrp
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
CN109432078B (zh) 2018-12-04 2020-09-01 南华大学 一种化合物在制备预防或治疗电离辐射所致认知障碍药物中的应用
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
TW202115095A (zh) 2019-08-16 2021-04-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
EP4013761A1 (fr) 2019-08-16 2022-06-22 Inflazome Limited Dérivés de sulfonylurée macrocycliques utiles en tant qu'inhibiteurs de nlrp3
JP2022547882A (ja) 2019-09-06 2022-11-16 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤
US20230121952A1 (en) 2020-02-18 2023-04-20 Inflazome Limited Compounds

Also Published As

Publication number Publication date
UY37847A (es) 2019-03-29
JP2020531453A (ja) 2020-11-05
US20210130359A1 (en) 2021-05-06
US11613542B2 (en) 2023-03-28
AU2018317798A1 (en) 2020-02-13
EP3837242A1 (fr) 2021-06-23
CN112789264A (zh) 2021-05-11
KR20200041919A (ko) 2020-04-22
SG11202001166RA (en) 2020-03-30
CN111093773A (zh) 2020-05-01
CA3071150A1 (fr) 2019-02-21
WO2020035465A1 (fr) 2020-02-20
RU2020110219A (ru) 2021-09-17
EP3668599A1 (fr) 2020-06-24
IL272557A (en) 2020-03-31
CL2020000367A1 (es) 2020-08-28
MX2020001776A (es) 2020-03-24
PE20200758A1 (es) 2020-07-27
RU2020110219A3 (fr) 2022-02-15
US20210163412A1 (en) 2021-06-03
WO2019034690A1 (fr) 2019-02-21
BR112020003014A2 (pt) 2020-07-28
TW201910316A (zh) 2019-03-16

Similar Documents

Publication Publication Date Title
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
LT3661921T (lt) Selektyvūs nlrp3 inflamasomos inhibitoriai
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
IL272557A (en) Sulfonylureas and sulfonythioureas as NLRP3 inhibitors
PL3481852T3 (pl) Nowa neurotoksyna botulinowa i jej pochodne
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
EP3444254A4 (fr) Dérivé de pyridinopyrimidinone substitué hétérocyclique en tant qu'inhibiteur de cdk et son utilisation
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
PT3606519T (pt) Compostos de inibidor de ask1 e utilizações dos mesmos
MA46746A (fr) Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
EP3250367A4 (fr) Étalonnage d'agent